Drug Trial Radar · NCT04471922
A Multiple Ascending High Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
Last checked: Nov 19, 2026Latest source record: Jul 15, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Mar 21, 2019
Primary completion
Mar 28, 2019
Study completion Mar 28, 2019
Sponsor
- Lead sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 15, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A single-center, randomized, double-blinded, placebo parallel controlled phase 1 study to evaluate the safety and pharmacokinetics/pharmacodynamics of multiple (7 days) ascending dose (60mg QD, 80mg QD, 100mg Qd) administrationof Anaprazole in healthy Chinese subjects. 45 subjects, 15 subjects for each dose group. In each dose group, 10 subjects take investigational drug (anaprazole), 2 subjects take active comparatory drug (rabeprazole), 3 subjects take placebo.
Conditions
- Healthy Volunteers
Interventions
Anaprazole Sodium enteric-coated tabletDrug
Multiple ascendinng dose, anaprazole 60mg QD(60mg QD group), 80mg QD(80mg QD group), 100mg QD(100mg QD group) , 7 days, fasting oral administration.
PlaceboDrug
Multiple dose, 1 tablet QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
Active controlled (rabeprazole)Drug
Multiple dose, rabeprazole 20mg QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with adverse events and serious adverse events as assessed by CTCAE v5.0Time frame: From signing informed consent to study completion at 14 days after fist dose administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.